Boundless Bio

Boundless Bio Shares Outstanding

The The number of shares of Boundless Bio (BOLD) as of Nov 17, 2026 is 22.39 M. In the previous year, The number of shares was 22.39 M — a change of 0.00% (lower).

Shares Outstanding

22.39 M

YoY

0.00%

Last updated:

In 2025, Boundless Bio had 22.39 M outstanding stocks, a 0.00% change from the 22.39 M stocks in the previous year.

The Boundless Bio Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2023
22.39 M USD
Jan 1, 2024
22.39 M USD
Jan 1, 2025
22.39 M USD
Jan 1, 2026 (e)
22.36 USD
Jan 1, 2027 (e)
22.36 USD
Jan 1, 2028 (e)
22.36 USD
Jan 1, 2029 (e)
22.36 USD
Jan 1, 2030 (e)
22.36 USD
The Boundless Bio Shares Outstanding history
YEARShares OutstandingYoY
est22.360.00%
est22.360.00%
est22.360.00%
est22.360.00%
est22.36-100.00%
22.39 M0.00%
22.39 M0.00%
22.39 M0.00%
22.39 M0.00%
22.39 M0.00%
22.39 M0.00%
22.39 M0.00%
22.39 M—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Boundless Bio Number of shares

Boundless Bio shares outstanding

The number of shares of Boundless Bio was 22.36 M in 2025. This indicates how many shares Boundless Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2023
22.24 M Stocks
Jan 1, 2024
16.98 M Stocks
Jan 1, 2025
22.36 M Stocks
Jan 1, 2026 (e)
22.36 M Stocks
Jan 1, 2027 (e)
22.36 M Stocks
Jan 1, 2028 (e)
22.36 M Stocks
Jan 1, 2029 (e)
22.36 M Stocks
Jan 1, 2030 (e)
22.36 M Stocks

Boundless Bio Stock analysis

What does Boundless Bio do? Boundless Bio Inc generates revenue through its clinical-stage oncology platform focused on ecDNA-directed therapeutics. The company develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx), with lead candidates BBI-355 and BBI-825 targeting specific cancer mechanisms. BBI-355, an oral CHK1 inhibitor, is in Phase I/II trials for oncogene amplified cancers, while BBI-825 inhibits ribonucleotide reductase for ecDNA assembly. The company monetizes its proprietary Spyglass platform by identifying targets for ecDTx development, aiming to address unmet needs in cancer treatment through targeted therapies. Boundless Bio's primary customers are patients with oncogene amplified tumors seeking novel treatments, as well as clinical trial participants in its Phase I/II studies. The company's revenue streams are derived from its pipeline of ecDTx candidates, with BBI-355 and BBI-825 representing key products in development. These therapeutics target cancer cells' reliance on extrachromosomal DNA (ecDNA) for replication and transcription, positioning the company in the oncology therapeutics segment for precision medicine approaches. The company's business model centers on developing ecDTx candidates through its Spyglass platform, which identifies essential targets for ecDNA functionality. BBI-355 and BBI-825 are the main products in its pipeline, with BBI-355 currently in clinical trials. Boundless Bio focuses on addressing unmet needs in oncology by targeting ecDNA mechanisms, differentiating its approach from traditional cancer therapies. The company's revenue potential is tied to the successful advancement of its clinical-stage candidates toward market approval. Boundless Bio is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Boundless Bio's Shares Outstanding

Boundless Bio's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Boundless Bio’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Boundless Bio’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Boundless Bio’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Boundless Bio stock

The number of shares of Boundless Bio is 22.39 M in 2025.

The number of shares of Boundless Bio changed from 22.39 M to 22.39 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Boundless Bio since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Boundless Bio

All Key Metrics — Boundless Bio